Literature DB >> 18477483

Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases.

Benjamin Bonavida1, Stavroula Baritaki, Sara Huerta-Yepez, Mario I Vega, Devasis Chatterjee, Kam Yeung.   

Abstract

The treatment of primary tumors results in an initial response to approved conventional therapeutics. However, recurrences and malignancies develop as a result of tumors' acquisition of anti-apoptotic mechanisms of resistance. Hence, there is an urgent need of novel therapeutics that can reverse resistance. One approach of interest is the inhibition of cell survival and anti-apoptotic pathways by sensitizing agents that can render resistant tumor cells sensitive to respond to various cytotoxic therapies. We have found that nitric oxide donors, similar to DETANONOate, inhibit cell survival anti-apoptotic pathways, such as the constitutively activated NF-kappaB and sensitize drug-resistant tumor cells to apoptosis by both chemotherapy and immunotherapy. Sensitization by DETANONOate was shown to inhibit the transcription repressor Yin Yang1 (YY1) shown to regulate resistance to both Fas ligand and TRAIL. In addition, DETANONOate-induced inhibition of NF-kappaB results downstream in the inhibition of several anti-apoptotic gene products, thus facilitating the activation of the apoptotic pathways with both chemotherapy and immunotherapy. In addition, DETANONOate induces the expression of the metastatic tumor suppressor gene product, Raf-1 Kinase Inhibitor Protein (RKIP), which inhibits the survival pathways induced by NF-kappaB and Raf-1/MEK which also contributes to the sensitizing activity. This indicates a novel finding that RKIP may also play an important role in the prevention of metastasis. Inhibition of NF-kappaB activation by DETANONOate results downstream in the inhibition of the RKIP transcription repressor Snail, resulting in upregulation of RKIP. Inhibition of Snail results in downstream inhibition of the metastatic cascade initiated by the epithelial-mesenchymal transition (EMT). Thus, nitric oxide donors have the dual functions of both sensitizing tumor cells to chemotherapy and immunotherapy and are also involved in the regulation and inhibition of metastasis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18477483     DOI: 10.1016/j.niox.2008.04.018

Source DB:  PubMed          Journal:  Nitric Oxide        ISSN: 1089-8603            Impact factor:   4.427


  29 in total

1.  Novel Nitric Oxide Donors of Phenylsulfonylfuroxan and 3-Benzyl Coumarin Derivatives as Potent Antitumor Agents.

Authors:  Yalan Guo; Yujie Wang; Haihong Li; Ke Wang; Qi Wan; Jia Li; Yubo Zhou; Ying Chen
Journal:  ACS Med Chem Lett       Date:  2018-04-20       Impact factor: 4.345

2.  Effects of nitric oxide on the biological behavior of HepG2 human hepatocellular carcinoma cells.

Authors:  Lei Zhou; Heng Zhang; Jie Wu
Journal:  Exp Ther Med       Date:  2016-03-02       Impact factor: 2.447

Review 3.  Combination of nitric oxide and drug delivery systems: tools for overcoming drug resistance in chemotherapy.

Authors:  Jihoon Kim; Bryant C Yung; Won Jong Kim; Xiaoyuan Chen
Journal:  J Control Release       Date:  2016-12-26       Impact factor: 9.776

4.  Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI.

Authors:  Claudia Weidensteiner; Wilfried Reichardt; Paul J Shami; Joseph E Saavedra; Larry K Keefer; Brunhilde Baumer; Anna Werres; Robert Jasinski; Nadja Osterberg; Astrid Weyerbrock
Journal:  Nitric Oxide       Date:  2013-01-28       Impact factor: 4.427

5.  Six degrees of separation: the oxygen effect in the development of radiosensitizers.

Authors:  Bryan T Oronsky; Susan J Knox; Jan Scicinski
Journal:  Transl Oncol       Date:  2011-08-01       Impact factor: 4.243

6.  Near-Infrared Photoactivatable Nitric Oxide Donors with Integrated Photoacoustic Monitoring.

Authors:  Effie Y Zhou; Hailey J Knox; Christopher J Reinhardt; Gina Partipilo; Mark J Nilges; Jefferson Chan
Journal:  J Am Chem Soc       Date:  2018-09-10       Impact factor: 15.419

7.  Nitric oxide: Friend or Foe in Cancer Chemotherapy and Drug Resistance: A Perspective.

Authors:  Birandra K Sinha
Journal:  J Cancer Sci Ther       Date:  2016-10-28

8.  Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy.

Authors:  Jonathan M Weiss; Lisa A Ridnour; Tim Back; S Perwez Hussain; Peijun He; Anna E Maciag; Larry K Keefer; William J Murphy; Curtis C Harris; David A Wink; Robert H Wiltrout
Journal:  J Exp Med       Date:  2010-10-04       Impact factor: 14.307

Review 9.  Nitric oxide and cancer: a review.

Authors:  Sheetal Korde Choudhari; Minal Chaudhary; Sachin Bagde; Amol R Gadbail; Vaishali Joshi
Journal:  World J Surg Oncol       Date:  2013-05-30       Impact factor: 2.754

10.  Loss of RKIP expression is associated with poor survival in GISTs.

Authors:  Olga Martinho; António Gouveia; Paula Silva; Amadeu Pimenta; Rui Manuel Reis; José Manuel Lopes
Journal:  Virchows Arch       Date:  2009-08-25       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.